$2.15 Billion is the total value of Cormorant Asset Management, LP's 73 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 7.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TPTX | Sell | TURNING POINT THERAPEUTICS I | $136,517,000 | -35.5% | 3,056,797 | -10.0% | 6.34% | -24.9% |
| CCXI | Sell | CHEMOCENTRYX INC | $81,365,000 | -29.1% | 2,025,000 | -30.2% | 3.78% | -17.4% |
| RETA | Sell | REATA PHARMACEUTICALS INCcl a | $70,323,000 | -57.9% | 487,206 | -40.3% | 3.27% | -50.9% |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $65,340,000 | -60.5% | 850,000 | -33.7% | 3.04% | -54.0% |
| CNST | Sell | CONSTELLATION PHARMACEUTICALS I | $64,118,000 | -40.8% | 2,040,021 | -11.3% | 2.98% | -31.1% |
| APLS | Sell | APELLIS PHARMACEUTICALS INC | $60,709,000 | -26.6% | 2,266,108 | -16.1% | 2.82% | -14.5% |
| STOK | Sell | STOKE THERAPEUTICS INC | $39,154,000 | -22.7% | 1,709,765 | -4.4% | 1.82% | -10.0% |
| BHVN | Sell | BIOHAVEN PHARMACTL HLDG CO L | $29,795,000 | -45.3% | 875,551 | -12.4% | 1.38% | -36.3% |
| AXSM | Sell | AXSOME THERAPEUTICS INC | $29,415,000 | -52.6% | 500,000 | -16.7% | 1.37% | -44.8% |
| ASND | Sell | ASCENDIS PHARMA A Ssponsored adr | $28,153,000 | -49.4% | 250,000 | -37.5% | 1.31% | -41.1% |
| NXTC | Sell | NEXTCURE INC | $27,558,000 | -51.1% | 743,400 | -25.7% | 1.28% | -43.1% |
| CRSP | Sell | CRISPR THERAPEUTICS AGnamen akt | $26,735,000 | -56.1% | 630,400 | -37.0% | 1.24% | -48.9% |
| RCKT | Sell | ROCKET PHARMACEUTICALS INC | $21,881,000 | -47.7% | 1,568,550 | -14.6% | 1.02% | -39.1% |
| AXNX | Sell | AXONICS MODULATION TECHNOLOG | $20,328,000 | -40.0% | 800,000 | -34.6% | 0.94% | -30.1% |
| GLPG | Sell | GALAPAGOS NVspon adr | $19,681,000 | -5.9% | 98,603 | -1.4% | 0.91% | +9.5% |
| IMVTU | Sell | IMMUNOVANT INCunit 12/18/2024 | $19,396,000 | -26.9% | 1,078,380 | -0.2% | 0.90% | -14.9% |
| TCDA | Sell | TRICIDA INC | $19,315,000 | -44.8% | 877,975 | -5.4% | 0.90% | -35.8% |
| STSA | Sell | SATSUMA PHARMACEUTICALS INC | $17,396,000 | +3.0% | 808,382 | -5.8% | 0.81% | +19.9% |
| CABA | Sell | CABALETTA BIO INC | $15,373,000 | -48.1% | 2,105,846 | -0.6% | 0.71% | -39.5% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $14,673,000 | -54.5% | 150,000 | -40.0% | 0.68% | -47.0% |
| DCPH | Sell | DECIPHERA PHARMACEUTICALS IN | $14,410,000 | -48.6% | 350,000 | -22.2% | 0.67% | -40.1% |
| AKRO | Sell | AKERO THERAPEUTICS INC | $13,622,000 | -17.1% | 642,539 | -13.2% | 0.63% | -3.5% |
| QTNT | Sell | QUOTIENT LTD | $12,488,000 | -62.5% | 3,161,500 | -9.7% | 0.58% | -56.3% |
| QURE | Sell | UNIQURE NV | $11,863,000 | -58.6% | 250,000 | -37.5% | 0.55% | -51.8% |
| ARGX | Sell | ARGENX SEsponsored adr | $10,538,000 | -34.4% | 80,000 | -20.0% | 0.49% | -23.6% |
| INSP | Sell | INSPIRE MED SYS INC | $9,042,000 | -29.3% | 150,000 | -12.9% | 0.42% | -17.6% |
| ALLK | Sell | ALLAKOS INC | $8,898,000 | -68.9% | 200,000 | -33.3% | 0.41% | -63.8% |
| KURA | Sell | KURA ONCOLOGY INC | $7,960,000 | -42.1% | 800,000 | -20.0% | 0.37% | -32.6% |
| HARP | Sell | HARPOON THERAPEUTICS INC | $7,527,000 | -21.7% | 649,993 | -0.0% | 0.35% | -8.9% |
| MRUS | Sell | MERUS N V | $7,260,000 | -48.4% | 600,000 | -40.0% | 0.34% | -40.0% |
| EIGR | Sell | EIGER BIOPHARMACEUTICALS INC | $5,543,000 | -55.4% | 815,127 | -2.2% | 0.26% | -48.0% |
| BCEL | Sell | ATRECA INC | $5,398,000 | +7.0% | 326,139 | -0.0% | 0.25% | +24.9% |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $4,200,000 | -46.3% | 100,000 | -42.0% | 0.20% | -37.5% |
| AMRN | Sell | AMARIN CORP PLCspons adr new | $3,600,000 | -87.1% | 900,000 | -30.8% | 0.17% | -85.0% |
| NKTR | Sell | NEKTAR THERAPEUTICS | $2,678,000 | -38.0% | 150,000 | -25.0% | 0.12% | -27.9% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $2,164,000 | -48.8% | 25,000 | -36.4% | 0.10% | -40.2% |
| DTIL | Sell | PRECISION BIOSCIENCES INC | $2,090,000 | -67.8% | 346,524 | -25.9% | 0.10% | -62.5% |
| GOSS | Sell | GOSSAMER BIO INC | $2,014,000 | -57.0% | 198,382 | -33.9% | 0.09% | -49.7% |
| ORTX | Sell | ORCHARD THERAPEUTICS PLCads | $1,933,000 | -59.9% | 256,649 | -26.7% | 0.09% | -53.1% |
| RARX | Exit | RA PHARMACEUTICALS INC | $0 | – | -295,600 | -100.0% | -0.55% | – |
| BHVN | Exit | BIOHAVEN PHARMACTL HLDG CO Lcall | $0 | – | -500,000 | -100.0% | -1.09% | – |
| XBI | Exit | SPDR SERIES TRUSTput | $0 | – | -500,000 | -100.0% | -1.90% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.